Bio-Techne (TECH) Income from Non-Controlling Interests (2020 - 2022)
Bio-Techne (TECH) recorded quarterly Income from Non-Controlling Interests of $179000.0 in Q3 2022, down 54.22% quarter-over-quarter from $391000.0 in Q2 2022, and up 128.23% on a YoY basis from $78428.5 in Q3 2021.
Bio-Techne (TECH) Income from Non-Controlling Interests (2020 - 2022) Analysis & Trends
Bio-Techne's Income from Non-Controlling Interests history runs 3 years deep, the most recent figure standing at $179000.0 for Q3 2022.
- In Q3 2022, Income from Non-Controlling Interests rose 128.23% year-over-year to $179000.0; the TTM figure through Jun 2023 stood at $179000.0 (up 102.0% YoY), while the FY2023 annual figure was $179000.0, up 102.0% from the prior year.
- Income from Non-Controlling Interests was $179000.0 for Q3 2022 at Bio-Techne, down from $391000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $391000.0 in Q2 2022 to a low of -$8.1 million in Q4 2021.
- Historically, Income from Non-Controlling Interests has averaged -$1.2 million across 3 years, with a median of -$348000.0 in 2021.
- The sharpest annual moves came in 2021 and 2022: Income from Non-Controlling Interests slumped 6141.54% in 2021, then soared 223.73% in 2022.
- A 3-year view of Income from Non-Controlling Interests shows it stood at -$130000.0 in 2020, then plunged by 6141.54% to -$8.1 million in 2021, then soared by 102.21% to $179000.0 in 2022.
- The last three Income from Non-Controlling Interests figures came in at $179000.0 (Q3 2022), $391000.0 (Q2 2022), and -$595000.0 (Q1 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Bio-Techne | 9.04 Bn | 8.83 Bn | 208.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 179,000.00 |
| Jun 30, 2022 | 391,000.00 |
| Mar 31, 2022 | -595,000.00 |
| Dec 31, 2021 | -8.11 Mn |
| Sep 30, 2021 | -634,000.00 |
| Jun 30, 2021 | -316,000.00 |
| Mar 31, 2021 | -380,000.00 |
| Dec 31, 2020 | -130,000.00 |